* Alzamend Neuro Inc is expected to show no change in quarterly revenue when it reports results for the period ending July 31 2023
*
* LSEG's mean analyst estimate for Alzamend Neuro Inc is for a loss of 67 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Alzamend Neuro Inc is $56.25, above its last closing price of $1.11.
This summary was machine generated December 8 at 21:12 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments